CD59 could inhibit complement and CD8+ T cell activation, leading to immune evasion and immune checkpoint blockade [56], which was also overexpressed in HNSCC and regulated tumor metastasis and prognosis [57–59]. This evidence concerns the gene CD59 and head and neck squamous cell carcinoma.